Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma

被引：2
|
作者：
Agarwala, Sanjiv S. [1 ,2 ]
Gray, Robert J. [3 ,4 ]
Wong, Michael K. K. [5 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] St Lukes Canc Ctr, Bethlehem, PA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Univ, Boston, MA 02115 USA
[5] GU Clin Roswell Pk Canc Inst, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 25期
关键词：
ADJUVANT THERAPY; TRIAL;
D O I：
10.1200/JCO.2009.23.0334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [21] Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, TJ
    Borden, EC
    Blum, RH
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 7 - 17
  • [22] Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    Kirkwood, JM
    Bender, C
    Agarwala, S
    Tarhini, A
    Shipe-Spotloe, J
    Smelko, B
    Donnelly, S
    Stover, L
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3703 - 3718
  • [23] Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma
    Lian, Bin
    Mao, Li Li
    Cui, Chuan Liang
    Chi, Zhi Hong
    Si, Lu
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients.
    Si, L.
    Mao, L. L.
    Chi, Z. H.
    Cui, C. L.
    Sheng, X. N.
    Li, S. M.
    Tang, B. X.
    Guo, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
    Kilbridge, KL
    Cole, BF
    Kirkwood, JM
    Haluska, FG
    Atkins, MA
    Ruckdeschel, JC
    Sock, DE
    Nease, RF
    Weeks, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1311 - 1318
  • [26] Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients
    Nicola Mozzillo
    Paolo Ascierto
    Clinical & Experimental Metastasis, 2012, 29 : 801 - 805
  • [27] Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma
    Dubois, RW
    Vetter, SMS
    Atkins, M
    McMasters, K
    Halbert, R
    Miller, SJ
    Shiell, R
    Kirkwood, J
    ARCHIVES OF DERMATOLOGY, 2001, 137 (09) : 1217 - 1224
  • [28] Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients
    Mozzillo, Nicola
    Ascierto, Paolo
    CLINICAL & EXPERIMENTAL METASTASIS, 2012, 29 (07) : 801 - 805
  • [29] Adjuvant therapy of high-risk melanoma: The role of high-dose interferon alpha-2b
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, T
    Borden, E
    Blum, R
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 251 - 257
  • [30] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
    Salans, Mia
    Courtney, Patrick Travis
    Yip, Anthony
    Murphy, James D.
    CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
12345